Dr. Paola Cecere
Paola Cecere obtained her M.Sc. in “Medicinal Chemistry and Pharmaceutical Technology” at the University of Bari. In 2013, she worked as a research fellow at the Center for Biomolecular Nanotechnologies (CBN) of IIT (Lecce), where, in 2014, she started her PhD in “Materials Science and Structural Engineering and Nanotechnologies.” Since 2015, she moved to the Central Research Labs of IIT in Genova, where she completed her PhD course and worked as a postdoctoral researcher from 2017 to 2020. From 2021 to 2023, she was the technical manager for MC Biotech srl, a start-up company in Sesto Calende (Lombardia), in the field of molecular diagnostics for human and veterinary applications. Since May 2023, she has been a postdoctoral researcher in the Nanobiointeractions & Nanodiagnostics Labs at Istituto Italiano di Tecnologia (IIT) in Genoa.
Her research is focused on the design and development of colorimetric and fluorescence-based diagnostic strategies, based on enzymatic or target/signal isothermal amplification reactions (such as LAMP), for point-of-care applications for human health and wellness, as well as food safety and traceability.
Dr. Pier Paolo Pompa
After his degree in Physics in 2005, Pier Paolo took a PhD in Nanoscience at the National Nanotechnology Laboratory (NNL) in Lecce. PPP subsequently joined NNL as a junior researcher and, since 2008, as a staff scientist. In 2009, he moved to the Center for Biomolecular Nanotechnologies (CBN) of IIT, where he was first appointed Coordinator of the Environment, Health and Safety (EHS) Research Platform and, in 2011, Director of CBN. In 2015, he moved to the Central Research Labs of IIT in Genova. He is also a Contract Professor at the University of Genova (Department of Biotechnology), a Member of the University Board for the PhD School (Department of Chemistry), an Editorial Board Member of several international journals, and a Member of the Scientific Committee of several international conferences.
His scientific activities are highly interdisciplinary, ranging from nanotechnology to biophysics, nanodiagnostics, nanomedicine, nanobiotechnology, and nanochemistry, and are intensively focused on the understanding of the interaction between nanomaterials and living systems and the development of low-cost hybrid sensing strategies, based on nanoparticles, for point-of-care diagnostics.
PPP has authored over 200 peer-reviewed publications in international journals (including Nature Nanotech, PNAS, Nature Comm, ACS Nano, Angew Chem, Adv Mater, and Chem Soc Rev, with >13,500 citations), several book chapters, and many invited and oral contributions to international conferences. He is also the author of over 35 international patents. He has led various national and international projects in the field of nanobiotechnology (>7.1 M€ of competitive grants). He is also a reviewer for major scientific journals (Nature Mater, Nature Nanotech, etc.) and international funding agencies (ISF, ACS, HFSP).
Dr. Giuseppina Sannino
Giuseppina is an accomplished professional in the area of molecular biology and serves as the Global Business Development Manager for Medix Biochemica’s MDx business. After achieving her PhD in Cancer Biology from the University of Tübingen, Giuseppina worked at MicroGEM, a novel nucleic acid extraction reagent manufacturer as Head of Business and Application Development (EMEA), before making the move to Medix Biochemica. Originally from Italy, Giuseppina is now based in Germany, and uses her impressive scientific background, in combination with her business knowledge, to spearhead the creation of strategic partnerships, along with driving business development and sales strategies on an international scale. Her focus encompasses Medix Biochemica's unique polymerases and suite of custom services.
Anthony Austin
Anthony is the Global Marketing Manager for Medix Biochemica, starting in 2022. He enters this role after 15 years holding various science focused responsibilities in R&D, Manufacturing, Analytical and Product Management. Prior to Medix Biochemica, he worked in academic labs studying bone metabolism and genetic diseases affecting white blood cells and their ability to fight infections.
.svg)
